References of "CHARLIER, Corinne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLaparoscopic Removal of Pheochromocytoma. Why? When? And Who? (Reflections on One Case Report)
Meurisse, Michel ULg; Joris, Jean ULg; Hamoir, Etienne ULg et al

in Surgical Endoscopy (1995), 9(4), 431-6

Until now, the need for wide exposure and nonmanipulative dissection of pheochromocytoma has dictated the use of a large intraperitoneal transabdominal approach, which unfortunately results in a ... [more ▼]

Until now, the need for wide exposure and nonmanipulative dissection of pheochromocytoma has dictated the use of a large intraperitoneal transabdominal approach, which unfortunately results in a significant incidence of morbidity. A unilateral retroperitoneal approach guided by the refinements of new imaging techniques is less invasive but is associated with a small risk of incomplete cure. In one case report, we tested the hypothesis that laparoscopic surgery could combine the beneficial effects of both operative strategies without their respective side effects. We concluded that a laparoscopic approach combined with exclusive intraoperative infusion of nicardipine, a calcium-channel blocker, can be used to surgically remove pheochromocytoma under stable hemodynamic conditions. This provides better exposure of the anatomical structures than open surgery and allows a visual exploration of the entire abdominal cavity to exclude tumor multicentricity or ectopic sites in the case of inconclusive preoperative imaging investigations. Moreover, conversion to open surgery is always possible if needed. [less ▲]

Detailed reference viewed: 25 (8 ULg)
Full Text
Peer Reviewed
See detailTamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells
Charlier, Corinne ULg; Chariot, Alain ULg; Antoine, Nadine ULg et al

in Biochemical Pharmacology (1995), 49

Tamoxifen (TAM), the non-steroidal anti-estrogen most widely administered to breast cancer patients, acts, at least in part, by competing with estrogen receptors (ER). However, the existence of an ... [more ▼]

Tamoxifen (TAM), the non-steroidal anti-estrogen most widely administered to breast cancer patients, acts, at least in part, by competing with estrogen receptors (ER). However, the existence of an alternative mechanism of action for this drug is supported by the clinical observations that: (a) 30% of patients with ER-negative cancer cells respond to TAM, and (b) 30% of patients with ER-positive cancer cells are not sensitive to this anti-estrogen. In this study, we observed that growth of the human ER-negative breast cancer cell line MDA-MB-435 was inhibited by TAM and 4-hydroxytamoxifen (4OH-TAM) in a concentration-dependent fashion. Both monoclonal enzymoimmunoassay and Dextran Charcoal Coated Scatchard radioimmunoassay analysis demonstrated that this MDA-MB-435 cell line does not express ER. The absence of ER in MDA-MB-435 cells was also demonstrated at the mRNA level by both northern blot hybridization and reverse transcription-polymerase chain reaction techniques. MDA-MB-435 cell proliferation was not affected by 17 beta-estradiol or by the pure anti-estrogen ICI 164384, further demonstrating that the observed effects of TAM and its active metabolite on the proliferation of MDA-MB-435 cells were due to an ER-independent mechanism, yet to be identified. MDA-MB-435 thus appears to be a promising original model for the study of the alternative ER-independent mechanisms of action of TAM. [less ▲]

Detailed reference viewed: 43 (12 ULg)
Peer Reviewed
See detailComparison of six serum ferritin immunoassays and isoferritin spectrotypes in malignancies
Vernet, M.; Renversez, J. C.; Lasne, Y. et al

in Annales de Biologie Clinique (1995), 53

Detailed reference viewed: 14 (0 ULg)
Peer Reviewed
See detailExploration biologique actuelle du métabolisme du fer
Charlier, Corinne ULg; Plomteux, Guy ULg

in Revue de la Médecine Générale (1995), 123

Detailed reference viewed: 25 (0 ULg)
See detailLa ciclosporine A
Charlier, Corinne ULg

Conference (1995)

Detailed reference viewed: 5 (0 ULg)
See detailToxicités aiguë et chronique des drogues toxicomanogènes
Charlier, Corinne ULg

Conference (1995)

Detailed reference viewed: 3 (0 ULg)
See detailLes traitements de substitution à la méthadone: le suivi en laboratoire
Charlier, Corinne ULg

Conference given outside the academic context (1995)

Detailed reference viewed: 10 (0 ULg)
See detailMechanism of action of Tamoxifen
Charlier, Corinne ULg

Conference (1995)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailTamoxifen activates the cell-cell adhesion function of E-Cadherin in MCF-7/6 human mammary carcinoma cells
Bracke, M.; Charlier, Corinne ULg; Bruyneel, E. et al

Poster (1994)

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailEtude comparative de six systèmes d'immunodosage de la ferritine sérique au cours de maladies rhumatismales
Revenant, M. C.; Vernet, M.; Rymer, J. C. et al

in Eurobiologiste (L') (1994), XXVIII(2), 35-41

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detailMarqueurs tumoraux
Charlier, Corinne ULg; Plomteux, Guy ULg

in Focus Diagnostica (1994), 2

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailTamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype
Bracke, M. E.; Charlier, Corinne ULg; Bruyneel, E. A. et al

in Cancer Research (1994), 54

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailLe tamoxifene dans le traitement du cancer du sein
Charlier, Corinne ULg; Colin, Claude ULg; Merville, Marie-Paule ULg et al

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (1994), 23(7), 751-6

Tamoxifen is the most often prescribed non steroidal antioestrogenic agent in the world for breast cancer. Worldwide collaboration. has centralized the results, of different trials throughout the world on ... [more ▼]

Tamoxifen is the most often prescribed non steroidal antioestrogenic agent in the world for breast cancer. Worldwide collaboration. has centralized the results, of different trials throughout the world on oral adjuvant therapy in the early stages of breast cancer. A significative regression of the tumour was observed in most cases. Moreover, recent epidemiological studies suggest that tamoxifen could prevent new contralateral primary tumours. The risk of the disease should thus be reduced by the prophylactic use of antioestrogens such as tamoxifen. Investigations using a variety of models have evaluated the effect of tamoxifen on tumour promotion and cell growth. Tamoxifen-induced growth inhibition is associated with major changes in biochemical events in cultured human breast cancer cells including cell proliferation or growth factor production. Growth inhibition of oestrogen-responsive human breast cancer cells is associated with an induced secretion of autoinhibitory polypeptides (TGF beta) and an antagonistic effect on the synthesis of proliferative proteins (TGF alpha,...). The first step in the mechanism of action of the drug is binding of tamoxifen to the oestrogen receptors. Development of resistance to tamoxifen treatment is a great problem in treatment of breast cancer patients and the mechanism of resistance will require further study: under the influence of the drug, tumours could become remodelled as selected subpopulations emerge resistant-tamoxifen. The fact that some breast cancers which are oestrogen receptor-negative respond to antioestrogen suggests that parallel but separate pathways for oestrogen and antioestrogen action may exist. This paper summarizes the results of the most recent studies concerning this promising drug. [less ▲]

Detailed reference viewed: 210 (11 ULg)
See detailRôle du laboratoire dans les intoxications aiguës
Charlier, Corinne ULg

Conference (1994)

Detailed reference viewed: 19 (0 ULg)